Short-Term Outcomes of Phage-Antibiotic Combination Treatment in Adult Patients with Periprosthetic Hip Joint Infection
Viruses · 2023
DOI: 10.3390/v15020499 ↗Kurz gefasst
Kontrollierte klinische Studie in der Zeitschrift Viruses, 2023. Verfasst von Eugeny Fedorov und 8 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedics Department, Novosibirsk Research Institute of Traumatology and Orthopedics, 630091 Novosibirsk, Russia. Hauptthemen laut MEDLINE: Arthritis, Infectious, Bacteriophages. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of Russian Federation, project for ICBFM SB RAS.
Abstract (Originalsprache)
Implant-associated infections are the most costly problem in modern orthopedics due to the continued increase in the occurrence of antibiotic-resistant bacterial strains that requires the development of new effective antimicrobials. A non-randomized, prospective, open-label, with historical control study on the use of combined phage/antibiotic therapy of periprosthetic joint infection (PJI) was carried out. Forty-five adult patients with deep PJI of the hip joint were involved in the study, with a 12-month follow-up after one-stage revision surgery. Patients from a prospective study group (SG, n = 23) were treated with specific phage preparation and etiotropic antibiotics, whereas patients from a retrospective comparator group (CG, n = 22) received antibiotics only. The rate of PJI relapses in the SG was eight times less than that in the CG: one case (4.5%) versus eight cases (36.4%), p = 0.021. The response rate to treatment was 95.5% (95% confidence interval (CI) = 0.7511–0.9976) in the SG and only 63.6% (95% CI = 0.4083–0.8198) in the CG. The odds ratio for PJI relapse in patients of the SG was 0.083 (95% CI = 0.009–0.742), which was almost 12 times lower than that in the CG. The obtained results support the efficacy of the combined phage-antibiotic treatment of PJI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Orthopedics Department, Novosibirsk Research Institute of Traumatology and Orthopedics, 630091 Novosibirsk, Russia.
- Biotechnology Department, Novosibirsk State Technical University, 630073 Novosibirsk, Russia.
- Laboratory of Molecular Microbiology, Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
- Biostatistics Department, Bekhterev National Medical Research Center for Psychiatry and Neurology of the Ministry of Health of the Russian Federation, 192019 Saint-Petersburg, Russia.
ORCID-Profile: Alexander Samokhin
Förderung
- Ministry of Science and Higher Education of Russian Federation, project for ICBFM SB RAS
Zitieren
APA
Fedorov, E., Samokhin, A., Kozlova, Y., Kretien, S., Sheraliev, T., Morozova, V., Tikunova, N., Kiselev, A., & Pavlov, V. (2023). Short-Term Outcomes of Phage-Antibiotic Combination Treatment in Adult Patients with Periprosthetic Hip Joint Infection. Viruses. https://doi.org/10.3390/v15020499
Vancouver
Fedorov E, Samokhin A, Kozlova Y, Kretien S, Sheraliev T, Morozova V, et al. Short-Term Outcomes of Phage-Antibiotic Combination Treatment in Adult Patients with Periprosthetic Hip Joint Infection. Viruses. 2023. doi:10.3390/v15020499
BibTeX
@article{Fedorov2023,
author = {Fedorov, Eugeny and Samokhin, Alexander and Kozlova, Yulia and Kretien, Svetlana and Sheraliev, Taalai and Morozova, Vera and Tikunova, Nina and Kiselev, Alexey and Pavlov, Vitaliy},
title = {Short-Term Outcomes of Phage-Antibiotic Combination Treatment in Adult Patients with Periprosthetic Hip Joint Infection},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15020499}
}
EUVIMED